Wire
UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating
UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating
$AMRX
$AMRX
7 stories mentioning AMRXUpdated 15d ago
Every FINWIRES story that references AMRX, newest first.
Wire
Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program
Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) are among the first seven companies selected by the U.S. Food and Drug Administration for a pilot program aimed at accelerating reviews of new domestic manufacturing facilities, CNBC reported Monday, citing FDA spokesperson Benjamin Nichols.The other participants in the FDA's PreCheck pilot program are Amneal Pharmaceuticals (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, the report said.The program allows regulators to begin reviewing new manufacturing facilities while they are still under construction, which the agency estimates could save companies up to 14 months, according to the report.Eli Lilly, Regeneron and FDA did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1228.24, Change: $+20.12, Percent Change: +1.67%
$AMRX$LLY$REGN
Sectors
Sector Update: Healthcare
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) declined 0.5%.In corporate news, Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary. Amneal Pharmaceuticals' shares rose 2.1%.
$AMRX
Sectors
Sector Update: Healthcare Stocks Rise Premarket Friday
Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.Amneal Pharmaceuticals (AMRX) stock was up more than 2% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.BioCardia (BCDA) has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said. Shares of BioCardia were up more than 33% pre-bell.
$AMRX$BCDA$IBB$XLV
Sectors
Sector Update: Healthcare
Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.Amneal Pharmaceuticals (AMRX) stock was up more than 1% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.
$AMRX
Sectors
Sector Update: Healthcare Stocks Rise Premarket Thursday
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.Royal Philips (PHG) and WellSpan Health said they have entered into a seven-year partnership focused on research, innovation, and the deployment of advanced imaging and diagnostic technologies across WellSpan's network. Shares of Royal Philips were up more than 1% pre-bell.Amneal Pharmaceuticals (AMRX) stock was 1% higher after the company said has received the US Food and Drug Administration's approval for its romidepsin injection solution.
$AMRX$BIIB$IBB$PHG$XLV
Research
UBS Initiates Amneal Pharmaceuticals at Buy With $19 Price Target
Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $17.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
$AMRX
